FDA approves Ionetix gallium-68 PSMA-11 for prostate cancer imaging

Another approved Ga-68 PSMA-11 supplier changes the conversation in nuclear medicine from pure regulation to market structure. Ionetix said the U.S. Food and Drug Administration approved its abbreviated new drug application for gallium Ga-68 gozetotide, also known as PSMA-11, on May 26, 2026, and the company said it became the first commercial drug manufacturer to receive ANDA approval for the product.

That matters because PSMA-PET has moved from specialty use into routine prostate cancer workups, and the bottleneck is not just clinical demand. Gallium-68 is a radioisotope, and access depends on how well producers can move short-lived material through cyclotrons, generators, radiopharmacies and PET sites without losing usable activity along the way. Ionetix framed its approval as a way to supply doses to underserved areas through its existing multi-site network of PET facilities, a sign that redundancy and distribution are now as important as the label itself.

Jill Wilson, Ionetix vice president of regulatory affairs and quality assurance, said the company was excited to offer gallium Ga-68 gozetotide to enable PSMA-PET imaging of men with prostate cancer. The immediate question for the market is whether that promise translates into meaningful new capacity, or simply adds one more entrant to a still-constrained supply chain. In practical terms, another approved source can improve resilience if a scanner site loses access to a single manufacturer or transport lane; it can also sharpen pressure on pricing if supply widens enough to matter.

The approval lands in a market that has already been shaped by distribution logistics. The FDA first approved Ga-68 PSMA-11 in December 2020 for PET imaging of PSMA-positive lesions in men with prostate cancer, and the initial access path ran through the UCLA Biomedical Cyclotron Facility and the UCSF Radiopharmaceutical Facility. Telix later described Illuccix as the first commercially available FDA-approved product to enable wide accessibility to 68Ga-based PSMA-PET imaging in the United States, noting that it can be prepared with 68Ga from cyclotrons or generator systems and has a four-hour shelf life after radiolabeling. Another product, Gozellix, won approval in March 2025 and was reported to have a longer shelf life and broader distribution radius.

That competition reflects where the field has gone. The National Comprehensive Cancer Network includes PSMA-PET imaging modalities, including Ga-68 PSMA-11, and Journal of Nuclear Medicine literature has described PSMA PET/CT as a common staging tool for newly diagnosed high-risk and unfavorable intermediate-risk prostate cancer because it improved sensitivity and specificity over conventional imaging. Ionetix’s approval does not solve isotope scarcity on its own, but it does add another commercial lane into a market where every extra dose, mile of distribution, and hour of shelf life can decide whether a scan gets scheduled.